A multicenter study on the prognostic value of prednisone response in pediatric acute lymphoblastic leukemia.

ABSTRACT:

Background

Prednisone response (PR) remains a key early treatment indicator in pediatric acute lymphoblastic leukemia (ALL). However, its independent prognostic significance has waned with the advent of minimal residual disease (MRD)-guided risk assessment. Evaluating the enduring biological and clinical significance of PR, especially in high-risk subtypes, could enhance the precision of therapeutic approaches.

Methods

This retrospective study analyzed clinical data from 2,979 pediatric patients primarily diagnosed with acute lymphoblastic leukemia (ALL) and enrolled in the South China Children's Leukemia Group (SCCLG-ALL)-2016 Collaborative Group between October 2016 and June 2023. Patients were categorized into "good prednisone response" (GPR) and "poor prednisone response

SUBMITTER: Dai JT 

PROVIDER: S-EPMC12672685 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature